Cardiovasculaire Geneeskunde.nl

Emerging therapies in the management of atherothrombosis

Slides (presentatie) - Nov. 9, 2011

Emerging therapies in the management of atherothrombosis


Prof. Wouter Jukema – Cardiologist
Leids University Medical Center, Leiden, The Neterhlands

 


Bekijk of download de presentatie

klik voor bekijken op onderstaande afbeeldingen





Cardiovascular Exchange Summit 2011


Assess bleeding risk

Limitations of current anticoagulants

Desirable qualities of a new anticoagulant

The coagulation cascade

The role of thrombin in coagulation

Ximelagatran

RE-LY: study design

RE-LY: A Non-inferiority Trial

Trial Execution

Baseline Characteristics

Permanent Discontinuation

Stroke or Systemic Embolism

Conclusions

Conclusions

Dabigatran (D) is an alternative to VKA therapy

New Anti-Coagulants

Program of anti-Fxa in Afib

AVERROES design

apixaban

ROCKET AF Study design

ROCKET AF Primary Efficacy outcome

ROCKET AF outcome

New anti-thrombotic drugs in atrial-fibrillation Factor II en Xa inhibitors are on their way!

Clopidogrel Trials – ACS/CAD

Balance of Hemostasis and Thrombosis

Aspirin and P2Y12 ADP Antagonists: Mechanisms of Action

Clopidogrel resistance and ST

High on-treatment platelet reactivity

CLOVIS-2

Antiplatelet therapy in ACS:New agents P2Y12 inhib.

DISPERSE2 substudy in patients on chronic clopidogrel treatment

PLATO Study Design

PLATO: Efficacy and safety

TRITON-TIMI 38 Study Design

TRITON TIMI-38 overall efficacy and safety results

TRILOGY-ACS Trial Design

Updated 2011 recommendations for oral antiplatelet therapy in myocardial revascularisation: NSTE-ACS

Aspirin and P2Y12 ADP Antagonists: Mechanisms of Action

Background

Development Strategy for Thrombin Receptor Antagonist

TRA Background

Patients with high-risk Non-ST-Segment Elevation Acute Coronary Syndrome

Antiplatelet: vorapaxar (TRA)

APPRAISE-2 Efficacy

APPRAISE-2 Safety

APPRAISE

APPRAISE

ATLAS ACS-TIMI 46

ATLAS ACS-TIMI 51 study phase III efficacy and safety study

Improving outcomes with antithrombotics in patients at risk of vascular events

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: